CANF Stock Analysis: Buy, Sell, or Hold?
CANF - Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares
$3.01
-0.13 (-4.14%)
▼
5d:
-7.1%
30d:
-36.63%
90d:
+1307.2%
WAIT
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: Apr 13, 2026
12d
Get Alerted When CANF Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CANF shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CANF shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CANF is currently trading at $3.01, which is considered oversold relative to its 30-day fair value range of $3.29 to $4.78.
Technical Outlook: Technically, CANF is in a strong uptrend. The price is currently testing key support at $3.07. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: CANF has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.50 (+16.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CANF is in a strong uptrend. The price is currently testing key support at $3.07. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: CANF has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.50 (+16.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$3.29 -
$4.78
Company Quality Score
47/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
44.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BEARISH: Downward momentum (-4.1%)
- BULLISH: Trading below Wall St target ($3.50)
Fair Price Analysis
30-Day Fair Range
$3.29 -
$4.78
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$3.07
Resistance Level
$3.62
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-75.25
Wall Street Target
$3.50
(+16.3%)
Revenue Growth (YoY)
-36.1%
Share & Embed Analysis
Last updated: March 30, 2026 10:47 PM ET
Data refreshes hourly during market hours. Next update: 11:47 PM
Data refreshes hourly during market hours. Next update: 11:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CANF showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 62 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 53 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 61 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 58 HOLD |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
15 analysts |
$669 | 67 BUY |
